Other anti-inflammatory agents were also tested in their effectiveness by repurposed drugs for COVID-19 therapy and involved positive results under mediators such as inhibitors of C5, IL-1, JAK1, JAK2 and IL-33 and related to reducing release of TNF-α and IL-1β [92]. This evidence concerns the gene IL1A and COVID-19.